Volume 30, Number 4—April 2024
Research
Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan
Ryuichi Minoda Sada
, Hiroo Matsuo, Daisuke Motooka, Satoshi Kutsuna, Shigeto Hamaguchi, Go Yamamoto, and Akiko Ueda
, Hiroo Matsuo, Daisuke Motooka, Satoshi Kutsuna, Shigeto Hamaguchi, Go Yamamoto, and Akiko Ueda
Table 2
Antimicrobial drug susceptibility of clinical bacterial strains from 5 patients who tested positive for Clostridium butyricum in a single-institute, retrospective study, Osaka University Hospital, Japan, and 3 medicinal strains from different lot numbers of C. butyricum MIYAIRI 588 strain
| Category |
Patient strains |
Medicinal strains of CBM 588 |
|||||||
| Patient no. | 1 | 2 | 3 | 4 | 5 | ||||
| Strain no. |
114–4 |
129–32 |
180–11 |
181–16 |
216–41 |
No. 1 |
No. 2 |
No. 3 |
|
| Antimicrobial drug | |||||||||
| Penicillin | 0.25 | 0.25 | 0.5 | 0.5 | 0.25 | 0.25 | 0.25 | 0.25 | |
| Ampicillin | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.12 | 0.25 | 0.25 | |
| Cefotaxime | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | |
| Ceftriaxone | 8 | 8 | 16 | 8 | 16 | 8 | 16 | 8 | |
| Cefmetazole | ≤4 | ≤4 | 8 | ≤4 | ≤4 | ≤4 | ≤4 | ≤4 | |
| Imipenem | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |
| Meropenem | ≤0.12 | ≤0.12 | 0.5 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | ≤0.12 | |
| Sulbactam/ampicillin | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | |
| Clavulanic acid/amoxicillin | 0.25 | 0.25 | 0.5 | 0.25 | 0.25 | 0.12 | 0.25 | 0.12 | |
| Tazobactam/piperacillin | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | |
| Clindamycin | 0.5 | 0.25 | 0.5 | 0.5 | 0.25 | 0.25 | 0.5 | 0.25 | |
| Moxifloxacin | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | |
| Metronidazole | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | |
Page created: February 06, 2024
Page updated: March 20, 2024
Page reviewed: March 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.